{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:46Z","timestamp":1790361706295,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,8,20]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>18FDG PET\/CT is a very important staging tool for patients with PMBCL. Metabolic activity defined by TLG on the baseline PET scan is a powerful predictor of PMBCL outcome.<\/jats:p>","DOI":"10.1182\/blood-2014-12-616474","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T22:35:50Z","timestamp":1434666950000},"page":"950-956","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":153,"title":["Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma"],"prefix":"10.1182","volume":"126","author":[{"given":"Luca","family":"Ceriani","sequence":"first","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Medical Oncology, Policlinico S. Orsola-Malpighi, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Citt\u00e0 della Salute e della Scienza, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gotti","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cabras","sequence":"additional","affiliation":[{"name":"Hematology, Ospedale Businco, Cagliari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Hematology, Policlinico Careggi, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Gargantini","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Oncology, Azienda Ospedaliera ASMN IRCCS Reggio Emilia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Pinotti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale di Circolo Fondazione Macchi, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Onco-Hematology Department, Modena University, Modena, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Giovanella","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W. M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111905520088500_B1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hon.818","article-title":"Primary mediastinal B-cell lymphoma.","volume":"25","author":"Boleti","year":"2007","journal-title":"Hematol Oncol"},{"key":"2019111905520088500_B2","author":"Gaulard"},{"issue":"10","key":"2019111905520088500_B3","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma.","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111905520088500_B4","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111905520088500_B5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"2019111905520088500_B6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/asheducation-2008.1.349","article-title":"Primary mediastinal B-cell lymphoma.","author":"Johnson","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"15","key":"2019111905520088500_B7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111905520088500_B8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111905520088500_B9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111905520088500_B10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.bjc.6601460","article-title":"Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B\/VACOP-B.","volume":"90","author":"Todeschini","year":"2004","journal-title":"Br J Cancer"},{"issue":"14","key":"2019111905520088500_B11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111905520088500_B12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.1999.17.3.784","article-title":"Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group.","volume":"17","author":"Abou-Elella","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111905520088500_B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111905520088500_B14","author":"Moskowitz"},{"issue":"14","key":"2019111905520088500_B15","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma.","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6947","key":"2019111905520088500_B16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","article-title":"Diagnostic tests 2: Predictive values.","volume":"309","author":"Altman","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"2019111905520088500_B17","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0.","volume":"47","author":"Delbeke","year":"2006","journal-title":"J Nucl Med"},{"issue":"3","key":"2019111905520088500_B18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","article-title":"Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis.","volume":"2","author":"Larson","year":"1999","journal-title":"Clin Positron Imaging"},{"issue":"2","key":"2019111905520088500_B19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals.","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"issue":"5","key":"2019111905520088500_B20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111905520088500_B21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma.","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111905520088500_B22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.","volume":"50","author":"Itti","year":"2009","journal-title":"J Nucl Med"},{"issue":"1","key":"2019111905520088500_B23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111905520088500_B24","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax.","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2019111905520088500_B25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-012-2280-z","article-title":"Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.","volume":"40","author":"Van de Wiele","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2019111905520088500_B26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma.","volume":"53","author":"Fonti","year":"2012","journal-title":"J Nucl Med"},{"issue":"6","key":"2019111905520088500_B27","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.27855","article-title":"Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.","volume":"119","author":"Kim","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"2019111905520088500_B28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","article-title":"Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.","volume":"91","author":"Song","year":"2012","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111905520088500_B29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1349-7006.2011.02164.x","article-title":"Prognostic value of metabolic tumor volume on PET\u200a\/\u200aCT in primary gastrointestinal diffuse large B cell lymphoma.","volume":"103","author":"Song","year":"2012","journal-title":"Cancer Sci"},{"issue":"4","key":"2019111905520088500_B30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00277-012-1640-x","article-title":"Interim PET\/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.","volume":"92","author":"Yang","year":"2013","journal-title":"Ann Hematol"},{"issue":"9","key":"2019111905520088500_B31","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/MNM.0b013e32835673ec","article-title":"Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with high-grade non-Hodgkin\u2019s lymphoma.","volume":"33","author":"Manohar","year":"2012","journal-title":"Nucl Med Commun"},{"issue":"5","key":"2019111905520088500_B32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/ejh.12268","article-title":"F-18 FDG PET\/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.","volume":"92","author":"Gallicchio","year":"2014","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111905520088500_B33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","article-title":"Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma.","volume":"40","author":"Kim","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2019111905520088500_B34","first-page":"272","article-title":"Baseline total lesion glycolysis measured with (18)F-FDG PET\/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study.","volume":"3","author":"Esfahani","year":"2013","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"3","key":"2019111905520088500_B35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00259-009-1275-x","article-title":"Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.","volume":"37","author":"Cazaentre","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2019111905520088500_B36","author":"Savage"},{"issue":"2","key":"2019111905520088500_B37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.V91.2.717","article-title":"Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation.","volume":"91","author":"Sehn","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2019111905520088500_B38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2141.2005.05661.x","article-title":"Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.","volume":"130","author":"Hamlin","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111905520088500_B39","first-page":"1258","article-title":"Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.","volume":"87","author":"Zinzani","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"2019111905520088500_B40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj030","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.","volume":"17","author":"Savage","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111905520088500_B41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1634\/theoncologist.11-5-488","article-title":"Primary mediastinal large B-cell lymphoma.","volume":"11","author":"Savage","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"2019111905520088500_B42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00259-003-1375-y","article-title":"FDG-PET\/CT in re-staging of patients with lymphoma.","volume":"31","author":"Freudenberg","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2019111905520088500_B43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2008.04.015","article-title":"Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus.","volume":"73","author":"Zhong","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2019111905520088500_B44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2019111905520088500_B45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1245\/s10434-009-0719-7","article-title":"Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.","volume":"17","author":"Hyun","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2019111905520088500_B46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0.","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/8\/950\/1391337\/950.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/8\/950\/1391337\/950.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:52:25Z","timestamp":1574142745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/8\/950\/34706\/Utility-of-baseline-18FDGPETCT-functional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-12-616474","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]}}}